CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype

被引:18
作者
Duregon, Eleonora [1 ]
Senetta, Rebecca [7 ]
Pittaro, Alessandra [7 ]
di Cantogno, Ludovica Verdun [7 ]
Stella, Giulia [2 ,3 ]
De Blasi, Pierpaolo [4 ,5 ]
Zorzetto, Michele [2 ,3 ]
Mantovani, Cristina [6 ]
Papotti, Mauro [1 ]
Cassoni, Paola [7 ]
机构
[1] Univ Turin, San Luigi Hosp, Dept Oncol, Turin, Italy
[2] Univ Pavia, Dept Mol Med, Pneumol Unit, Lab Biochem & Genet, I-27100 Pavia, Italy
[3] Fdn IRCCS Policlin San Matteo, Pavia, Italy
[4] Univ Turin, Turin, Italy
[5] Coll Carlo Alberto, Turin, Italy
[6] Univ Turin, Dept Oncol, Radiat Oncol, I-10124 Turin, Italy
[7] Univ Turin, Dept Med Sci, I-10124 Turin, Italy
关键词
Caveolin; 1; brain metastasis; non-small-cell lung cancer; radiotherapy; GRADED PROGNOSTIC ASSESSMENT; BREAST-CANCER; CELL CARCINOMA; FOLLOW-UP; SURVIVAL; PROGRESSION; MANAGEMENT; ADENOCARCINOMA; RADIOSURGERY; MUTATIONS;
D O I
10.18632/oncotarget.4988
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Brain metastases develop in one-third of patients with non-small-cell lung cancer and are associated with a dismal prognosis, irrespective of surgery or chemoradiotherapy. Pathological markers for predicting outcomes after surgical resection and radiotherapy responsiveness are still lacking. Caveolin 1 has been associated with chemo- and radioresistance in various tumors, including non-small-cell lung cancer. Here, caveolin 1 expression was assessed in a series of 69 brain metastases from non-small-cell lung cancer and matched primary tumors to determine its role in predicting survival and radiotherapy responsiveness. Only caveolin 1 expression in brain metastasis was associated with poor prognosis and an increased risk of death (log rank test, p = 0.015). Moreover, in the younger patients (median age of <54 years), caveolin 1 expression neutralized the favorable effect of young age on survival compared with the older patients. Among the radiotherapy-treated patients, an increased risk of death was detected in the group with caveolin 1-positive brain metastasis (14 out of 22 patients, HR=6.839, 95% CI 1.849 to 25.301, Wald test p = 0.004). Overall, caveolin 1 expression in brain metastasis from non-small-cell lung cancer is independently predictive of worse outcome and radioresistance and could become an additional tool for personalized therapy in the critical subset of brain-metastatic non-small-cell lung cancer patients.
引用
收藏
页码:29626 / 29636
页数:11
相关论文
共 44 条
[1]   Risk factors affecting survival after brain metastases from non-small cell lung carcinoma: a follow-up study of 70 patients [J].
Abrahams, JM ;
Torchia, M ;
Putt, M ;
Kaiser, LR ;
Judy, KD .
JOURNAL OF NEUROSURGERY, 2001, 95 (04) :595-600
[2]  
Ando T, 2007, ONCOL REP, V18, P601
[3]  
[Anonymous], 2015, WHO Classification of Tumours. WHO classification of tumours of the lung, pleura, thymus and heart
[4]   Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system [J].
Barnholtz-Sloan, JS ;
Sloan, AE ;
Davis, FG ;
Vigneau, FD ;
Lai, P ;
Sawaya, RE .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2865-2872
[5]   Caveolin-1 in meningiomas:: expression and clinico-pathological correlations [J].
Barresi, V. ;
Cerasoli, S. ;
Paioli, G. ;
Vitarelli, E. ;
Giuffre, G. ;
Guiducci, G. ;
Tuccari, G. ;
Barresi, G. .
ACTA NEUROPATHOLOGICA, 2006, 112 (05) :617-626
[6]   Management of brain metastases from non-small cell lung cancer [J].
Baykara, Meltem ;
Kurt, Gokhan ;
Buyukberber, Suleyman ;
Demirci, Umut ;
Ceviker, Necdet ;
Algin, Efnan ;
Coskun, Ugur ;
Aykol, Sukru ;
Emmez, Hakan ;
Ozet, Ahmet ;
Benekli, Mustafa .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (04) :915-921
[7]   Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells [J].
Bélanger, MM ;
Gaudreau, M ;
Roussel, É ;
Couet, J .
CANCER BIOLOGY & THERAPY, 2004, 3 (10) :954-959
[8]   2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease [J].
Besse, B. ;
Adjei, A. ;
Baas, P. ;
Meldgaard, P. ;
Nicolson, M. ;
Paz-Ares, L. ;
Reck, M. ;
Smit, E. F. ;
Syrigos, K. ;
Stahel, R. ;
Felip, E. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1475-1484
[9]   Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC [J].
Brodie, Seth A. ;
Lombardo, Courtney ;
Li, Ge ;
Kowalski, Jeanne ;
Gandhi, Khanjan ;
You, Shaojin ;
Khuri, Fadlo R. ;
Marcus, Adam ;
Vertino, Paula M. ;
Brandes, Johann C. .
PLOS ONE, 2014, 9 (09)
[10]   Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma [J].
Campbell, L. ;
Jasani, B. ;
Edwards, K. ;
Gumbleton, M. ;
Griffiths, D. F. R. .
BRITISH JOURNAL OF CANCER, 2008, 98 (05) :931-940